ASTELLAS PHARMA
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- $22.5B
- Website
- https://www.astellas.com/
A Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary Disease
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-03-17
- Last Posted Date
- 2012-09-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 1009
- Registration Number
- NCT00862641
A Clinical Study to Determine the Effect of YM178 on the Pharmacokinetics of Warfarin in Healthy Subjects
Phase 1
Completed
- Conditions
- First Posted Date
- 2009-03-05
- Last Posted Date
- 2013-07-02
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 24
- Registration Number
- NCT00856570
A Study to Evaluate the Effect of Repeat Oral Doses of YM443 on Cardiac Repolarization in Healthy Adults
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-02-25
- Last Posted Date
- 2014-03-24
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 80
- Registration Number
- NCT00850746
Long-term Treatment Study of Certolizumab Pegol Without Coadministration of Methotrexate in Japanese Rheumatoid Arthritis (RA) Patients
- First Posted Date
- 2009-02-25
- Last Posted Date
- 2014-11-02
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 208
- Registration Number
- NCT00850343
Long-term Treatment Study of Certolizumab Pegol (CDP870) as Add-on Medication to Methotrexate in Japanese Rheumatoid Arthritis (RA) Patients
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-02-25
- Last Posted Date
- 2014-11-02
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 285
- Registration Number
- NCT00851318
A Long-term Study of YM178 in Symptomatic Overactive Bladder Patients
- First Posted Date
- 2009-02-10
- Last Posted Date
- 2016-01-05
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 204
- Registration Number
- NCT00840645
Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-01-22
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 347
- Registration Number
- NCT00826280
An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155
- First Posted Date
- 2009-01-07
- Last Posted Date
- 2015-09-04
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 10
- Registration Number
- NCT00818480
- Locations
- 🇺🇸
Institute for Drug Development, San Antonio, Texas, United States
🇺🇸South Texas Accelerated, San Antonio, Texas, United States
🇺🇸Huntsman Cancer Hospital, Salt Lake City, Utah, United States
An Open-Label Study of the Safety and Pharmacokinetics of Repeated-Dose Micafungin in Neonates
- First Posted Date
- 2009-01-07
- Last Posted Date
- 2013-03-06
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 13
- Registration Number
- NCT00818584
Comparison of Extended Release Tacrolimus (Advagraf) and Cyclosporine A Microemulsion on Renal Function in Healthy Volunteers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-01-07
- Last Posted Date
- 2014-07-09
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 18
- Registration Number
- NCT00818194
© Copyright 2024. All Rights Reserved by MedPath